Português | English

ISSN (Print): 2359-4802 | ISSN (Online): 2359-5647

Thumbnail Image 1

New Cholesterol Targets of SBC Guidelines on Dyslipidemia
Maria Eliane Campos Magalhães

Evidence from clinical trials and meta-analysis have demonstrated that the most effective LDL (low-density lipoprotein) cholesterol–lowering treatment is associated with unequivocal benefits for reducing atherosclerotic cardiovascular disease (ASCVD) events.1 More recently, clinical trials concluded that the addition of ezetimibe and of a new class of drugs, inhibitors of proprotein convertase subtilisin/kexine type 9 (iPCSK9), to statins, were able to reduce LDL-C to levels not previously achieved with the available therapy so far.2-4

Keywords: Atherosclerosis; Cholesterol / standards; Dyslipidemias; Risk Factor; Reference Standards.
Check the interview with the author Dr. Christianne Scaramello talking about the article "Study of the Use of Dabigatran in Brazilian Public Hospital Specialized in Cardiology" published in the July and August/2017 issue.

Thumbnail Image 1

NT-ProBNP at Admission Versus NT-ProBNP at Discharge as a Prognostic Predictor in Acute Decompensated Heart Failure
Janine Magalhães, Fábio Soares, Marcia Maria Noya-Rabelo, Gabriel Neimann, Lucas Andrade, Luis Correia

Thumbnail Image 1

The use of Cardiac 123I-mIBG Scintigraphy in Clinical Practice: The Necessity to Standardize!
Euclides Timóteo da Rocha, Wilson Eduardo Furlan Matos Alves, Derk O. Verschure e Hein J Verberne

Check out the interview of the IJCS editor-in-chief, Dr. Claudio Tinoco, on the topics addressed in the articles: "Challenges for Contemporary Medicine" and "C-Reactive Protein in Oral Contraceptive Users".

IJCS - International Journal of Cardiovascular Sciences
Edition: 30.6 - 13 Articles


New Cholesterol Targets of SBC Guidelines on Dyslipidemia
Novas Metas de Colesterol da Diretriz de Dislipidemia da SBC

Maria Eliane Campos Magalhães
International Journal of Cardiovascular Sciences. 2017;30(6)466-468



NT-ProBNP at Admission Versus NT-ProBNP at Discharge as a Prognostic Predictor in Acute Decompensated Heart Failure
O NT-ProBNP da Admissão Versus da Alta como Preditor Prognóstico na Insuficiência Cardíaca Agudamente Descompensada

Janine Magalhães, Fábio Soares, Marcia Maria Noya-Rabelo, Gabriel Neimann, Lucas Andrade, Luis Correia
International Journal of Cardiovascular Sciences. 2017;30(6)469-475

+   Abstract  
Background: Patients admitted for decompensated heart failure (HF) receive intensive diuretic and vasodilator therapy in the first days. Normally, this is a successful approach that leads to HF compensation and hospital discharge. However, recurrences within the first week of discharge are common.
Objective: to evaluate whether the main predictor of recurrent outcomes in patients with HF is the severity of decompensation at admission or patient’s blood volume after clinical management.
Methods: Prospective, cohort study of patients admitted between January 2013 and October 2014, with diagnosis of acute decompensated HF, who were followed-up for 60 days after discharge. Inclusion criterion was increased plasma NT-proBNP (> 450 pg/mL for patients younger than 50 years or > 900 pg/mL for patients older than 50 years). Primary outcome was the combination of cardiovascular death with rehospitalization for decompensated HF in 60 days.
Results: Ninety patients were studied, with median NT-proBNP at admission of 3,947pg/mL (IQR: 2,370 – 7,000 pg/mL), and median NT‑proBNP at discharge of 1,946pg/mL (IQR: 1,000 – 3,781 pg/mL). The incidence of combined outcome was 30% (12.2% of deaths and 20% of rehospitalization). The area under the ROC curve for NT-proBNP at admission and 60-day cardiovascular events was 0.49 (p = 0.89; 95% CI = 0.36 – 0.62). The area under the curve of NT‑proBNP absolute variation for 60 day-events was 0.65 (p = 0.04; 95%CI = 0.51 – 0.79), and the area under the curve for NT-BNP at discharge was 0.69 (p = 0.03; 95%CI = 0.58 – 0.80). In the multivariate analysis, pre-discharge NT-proBNP was a predictor of the primary outcome, independently of the NT-proBNP at admission and other risk factors.
Conclusion: Different from the severity of decompensation at hospitalization, blood volume after compensation of HF is associated with recurrent event. This finding suggests that, regardless of initial severity, therapy response during hospitalization is determinant of the risk of recurrent decompensation. (Int J Cardiovasc Sci. 2017;30(6)469-475)

Keywords: Heart Failure / therapy; Heart Failure / mortality; Ventricular Dysfunction; Natriuretic Peptide; Hospitalization.


Safflower Oil (Carthamus tinctorius L.) Intake Increases Total Cholesterol and LDL-cholesterol Levels in an Experimental Model of Metabolic Syndrome
Óleo de Cártamo (Carthamus tinctorius) Aumenta os Níveis de Colesterol Total e LDL‑Colesterol em Modelo Experimental de Síndrome Metabólica

Lidiani Figueiredo Santana, Thaisa da Silva Dutra, Marcos Alexandre de Souza, Karine de Cássia Freitas, Silvia Aparecida Oesterreich, Cândida Aparecida Leite Kassuya, Fabíola Lacerda Pires Soares
International Journal of Cardiovascular Sciences. 2017;30(6)476-483

+   Abstract  
Background: Overweight has been considered an important public health problem. To reverse this situation, various types of treatment are proposed. The safflower oil (Carthamus tinctorius L.) has been used in the prevention/treatment of obesity.
Objectives: The aim of this study was to evaluate the therapeutic effects of this oil in an experimental model of metabolic syndrome.
Methods: Male Wistar rats initially received a highly palatable (HP) diet for ten weeks for validation of a metabolic syndrome model. Following confirmation, the animals were treated with a HP diet and soybean oil (HPSO) or safflower oil (HPSA) supplementation (1.0 mL/1000 g of animal weight). At the end of the experiment, the body composition, lipid profile and blood glucose levels of the animals were assessed. Student t test was used for statistical analysis.
Results: In the first stage (induction of metabolic syndrome), the animals given the HP diet showed gain weight (p < 0.001), visceral adiposity (p = 0.001), and significantly higher levels of blood glucose (p = 0.001) and triglycerides (p = 0.03) than those of the control group. Also, there was a difference in liver weight (p = 0.01). These results demonstrate that the HP diet administration is an effective model for the experimental metabolic syndrome study. In the second stage, the animals of the HPSA group showed increased total cholesterol (p < 0.05) and LDL-cholesterol (p < 0.001) levels.
Conclusion: Under the referred experimental conditions, the use of safflower oil can cause possible deleterious effects on the lipid profile in a metabolic syndrome experimental model. (Int J Cardiovasc Sci. 2017;30(6)476-483)

Keywords: Oils; Carthamus; Cholesterol; Metabolic Syndrome; Dyslipidemias; Obesity / prevention & control.


A Simpler and Shorter Neuromuscular Electrical Stimulation Protocol Improves Functional Status and Modulates Inflammatory Profile in Patients with End-Stage Congestive Heart Failure
Um Protocolo mais Simples de Eletroestimulação Neuromuscular Periférica Melhora a Capacidade Funcional de Pacientes com Insuficiência Cardíaca Grave

Maria Carolina Basso Sacilotto, Carlos Fernando Ramos Lavagnoli, Lindemberg Mota Silveira-Filho, Karlos Alexandre de Souza Vilarinho, Elaine Soraya Barbosa de Oliveira, Daniela Diógenes de Carvalho, Pedro Paulo Martins de Oliveira, Otávio Rizzi Coelho-Filho, Orlando Petrucci Junior
International Journal of Cardiovascular Sciences. 2017;30(6)484-495

+   Abstract  
Background: Neuromuscular electrical stimulation (NMES) using a stimulation wave for 5 days/week over 8 weeks has been used as a treatment option for congestive heart failure (CHF) patients who are unable to tolerate aerobic exercise.
Objective: We assessed the impact of a shorter NMES protocol using a Russian stimulation wave on the functional status, quality of life (QoL) and inflammatory profile of end-stage CHF patients.
Methods: Twenty-eight patients with end-stage CHF (53 ± 11 years) were randomized to the NMES or control group. Treatment was an NMES training program with Russian stimulation wave, applied for 50 minutes to both quadriceps femoral muscles twice weekly over seven weeks. The stimulation intensity was chosen to elicit muscle contractions in the NMES group and current input up to sensory threshold in the control group. Distance in the 6-minute walk test (6MWT) and QoL score by the Minnesota Living with Heart Failure Questionnaire were evaluated before, immediately after and one month after NMES protocol completion. Peripheral leukocytes were obtained to measure the gene expression levels of inflammatory cytokines.
Results: The NMES group showed increases in the 6MWT (324 ± 117 vs. 445 ± 100 m; p = 0.02) and QoL score (64 ± 22 vs. 45 ± 17; p < 0.01) immediately but not 1 month after protocol completion, as well as increased gene expression levels of IL-1β, IL-6 and IL-8 after protocol completion.
Conclusion: Using a shorter and fewer sessions NMES protocol improved the QoL score and functional class of severe CHF patients, and modulated the gene expression levels of some cytokines. This protocol might be a good alternative for patients with severe CHF and limitations in protocol adherence. (Int J Cardiovasc Sci. 2017;30(6)484-495)

Keywords: Heart Failure; Exercise Tolerance; Electric Stimulation Therapy / adverse effects; Exercise; Rehabilitation; Heart Transplantation.


Cirrhotic Patients with Child-Pugh C Have Longer QT Intervals
Pacientes Cirróticos com Escore Child-Pugh C Apresentam Intervalos QT mais Longos

Pedro Gemal Lanzieri, Ronaldo Altenburg Gismondi, Matheus de Castro Abi-Ramia Chimelli, Raíssa Pereira Cysne, Thais Guaraná, Cláudio Tinoco Mesquita, Luís Otávio Mocarzel
International Journal of Cardiovascular Sciences. 2017;30(6)496-503

+   Abstract  
Background and aims: Cirrhotic cardiomyopathy has been used to describe chronic cardiac dysfunction in cirrhotic patients with no previous structural heart disease. Additionally, QT prolongation is one of the most important cardiac alterations related to cirrhosis. Previous studies suggest that QT prolongation is associated with a higher mortality rate among cirrhotic patients. The aim of this study was to analyze QT intervals according to cirrhosis severity as measured by the Child-Pugh classification.
Materials and methods: In a cross-sectional study, a total of 67 patients with nonalcoholic cirrhosis underwent clinical and electrocardiographic evaluation. Cirrhosis severity was classified according to the Child-Pugh score. The QT interval was measured by a 12-lead electrocardiogram.
Results: The QT intervals were longer in patients in the Child-Pugh C group than those in the Child-Pugh A and B groups (459 ± 33 vs 436 ± 25 and 428 ± 34 ms, respectively, p = 0.004). There was a positive correlation between the QT interval and the Child-Pugh score in individuals with Child-Pugh scores ≥ 7 (r = 0.50, p < 0.05) and QT intervals ≥ 440 ms (r = 0.46, p < 0.05).
Conclusion: The present study showed longer QT intervals in patients with Child-Pugh C cirrhosis, which reinforced the relationship between the severity of cirrhosis and electrocardiographic findings of cirrhotic cardiomyopathy. Moreover, this finding emerged in patients with no cardiac symptoms, which highlighted the importance of a simple and noninvasive method (ECG) to identify cirrhotic patients with cardiomyopathy. (Int J Cardiovasc Sci. 2017;30(6)496-503)

Keywords: Cardiomyopathies; Liver Cirrhosis / mortality; Long QT Syndrome; Electrocardiography / methods.


Predictors for Indication to Catheterization after Myocardial Perfusion Gated Spect
Preditores da Indicação de Coronariografia Pós-Cintilografia Miocárdica de Perfusão

Fernanda de Oliveira Mesquita, Larissa Andrade, Lívia Pitta, Andrea Rocha de Lorenzo, Ronaldo de Souza Leão Lima
International Journal of Cardiovascular Sciences. 2017;30(6)504-509

+   Abstract  
Background: Patients with coronary artery disease with left ventricular dysfunction present higher mortality and are the major beneficiaries of a myocardial revascularization procedure. A previous study showed that left ventricular ejection fraction (LVEF) is a negative determinant for cardiac catheterization (CAT) after myocardial perfusion scintigraphy (MPS).
Objective: To determine clinical and scintigraphic factors associated with cardiac catheterization (CAT) indication in patients undergoing myocardial perfusion SPECT (MPS).Population: Patients consecutively submitted to PMC in the period from March 2008 to December 2012.
Methods: All patients undergoing MPS during the study were recorded in a data bank, where epidemiological, clinical and scintigraphic data (perfusion scores and LVEF) were recorded. Patients or their attending physicians were contacted by phone semiannually for follow-up. For statistical analysis, univariate analyzes were performed and variables were selected for inclusion in a logistic regression model.
Results: 5536 patients were submitted to MPS, of which 643 performed CAT after the examination. This group presents a higher prevalence of males, hypertensive, dyslipidemic and previously revascularized. Patients undergoing CAT have angina more frequently, more extensive ischemia scores and lower LVEF. Only presence of angina (IC 95% 1.2 - 1.7, p < 0.001) and extent of ischemia (95% CI 1.2 - 1.3, p < 0.001) were independent variables for CAT indication.
Conclusion: The presence of angina and the extent of ischemia were the main predictors for CAT post-MPS indication while lower LVEF was not an independent predictor. (Int J Cardiovasc Sci. 2017;30(6)504-509)

Keywords: Coronary Diseases; Ventricular Dysfunction, Left/mortality; Cardiac Catheterization; Myocardial/diagnostic imaging.


Assessment of Central Blood Pressure and Arterial Stiffness in Practicing Long-Distance Walking Race
Avaliação da Medida Central da Pressão e Rigidez Arterial em Participantes de Caminhada de Longa Distância

Edison Nunes Pereira, Priscila Valverde de Oliveira Vitorino, Weimar Kunz Sebba Barroso de Souza, Mariana Cardoso Pinheiro, Ana Luiza Lima Sousa, Paulo Cesar Brandão Veiga Jardim, Jeeziane Marcelino Rezende, Antonio Coca
International Journal of Cardiovascular Sciences. 2017;30(6)510-516

+   Abstract  
Background: An ecological hiking occurs yearly in Brazil. It is a unique event because of its distance (310 km) and dynamics (mean of 62 km/day for 5 days with mean pace of 7.6 km/h). Although beneficial effects of moderate‑intensity exercises are well-known, the effects of intense and long-duration exercise still require study.
Objective: To evaluate the effects of mixed walking/running race on various blood pressure (BP) parameters 30 days before (A0), on the 2nd (A2), 3rd (A3), and 4th (A4) days after completing the day’s stage.
Methods: Central systolic (cSBP) and diastolic BP (cDBP), peripheral systolic (pSBP) and diastolic BP (pDBP), central pulse pressure (cPP), peripheral pulse pressure (pPP), amplified pulse pressure (aPP), corrected augmentation index (AIx75%) and pulse wave velocity (PWV) were measured using an oscillometric Mobil‑O‑Graph® (IEM, Stolberg, Germany) in 25 male athletes (mean age of 45.3 ± 9.1 years). A p value < 0.05 was considered a statistically-significant difference.
Results: cSBP decreased from A0 to A2 (109.5 to 118.1 mmHg) and from A0 to A3 (109.5 to 102.5 mmHg); pPP decrease from A0 to A2 (49.2 to 38.2 mmHg) and from A0 to A4 (49.2 to 41.2 mmHg); aPP decrease from A0 to A1 (15.6 to 9.5 mmHg), from A0 to A2 (15.6 to 8.0 mmHg) and from A0 to A3 (15.6 to 11.2 mmHg). PWV correlated with age.
Conclusions: Blood pressure dropped on the first days of the race and returned to close to baseline values at the end. PWV correlates strongly with age. This type of exercise promotes effects on BP and PWV similar to those seen in long-duration, high-intensity sports. These changes in trained healthy individuals do not seem to increase cardiovascular risks. This was the first study to assess the effects of this type of exercise on the cardiovascular system. (Int J Cardiovasc Sci. 2017;30(6)510-516)

Keywords: Hypertension; Blood Pressure; Vascular Stiffness; Exercise; Walking; Pulse Wave Analysis.


Use of HAS-BLED Score in an Anticoagulation Outpatient Clinic of a Tertiary Hospital
Uso do Escore HAS-BLED em um Ambulatório de Anticoagulação de um Hospital Terciário

Rafael Coimbra Ferreira Beltrame, Franciele Taís Bandeira Giasson, André Luís Ferreira Azeredo da Silva, Bruna Sessim Gomes, Luís Carlos Amon, Marina Bergamini Blaya, Rafael Selbach Scheffel, Fernando Pivatto Júnior
International Journal of Cardiovascular Sciences. 2017;30(6)517-525

+   Abstract  
Background: HAS-BLED score was developed to assess 1-year major bleeding risk in patients anticoagulated with vitamin K antagonists (VKA) due to atrial fibrillation (AF).
Objective: Of this study was to assess the ability of HAS-BLED score and its components to predict major bleeding in patients treated in an anticoagulation outpatient clinic of a tertiary hospital.
Methods: A retrospective cohort study on AF patients treated with VKA was conducted. Logistic regression analysis was performed to evaluate the ability of individual score components to predict major bleeding. The significance level adopted in all tests was 5%.
Results: We studied 263 patients with a mean age of 71.1 ± 10.5 years over a period of 237.6 patients-year. Median HAS-BLED score was 2 (1-3). The overall incidence of major bleeding was 5.7%, and it was higher among high‑risk HAS-BLED score patients than in low risk patients (9.6 vs. 3.1%; p = 0.052). Area under the ROC curve was 0.70 (p = 0.01). Cut-off point ≥ 3 showed sensibility of 66.7%, specificity of 62.1%, positive predictive value of 9.6% and negative predictive value of 96.9%. Major bleeding-free survival was lower in high-risk group (p = 0.017). In multivariate analysis, concurrent antiplatelet use was the only independent predictor of major bleeding among score components (OR 5.13, 95%CI: 1.55-17.0; p = 0.007).
Conclusion: HAS-BLED score was able to predict major bleeding in this cohort of AF patients. Among score components, special attention should be given for concomitant antiplatelet use, which was independently associated to this outcome. Antiplatelets in AF patients under VKA anticoagulation should be used in selected patients with favorable risk-benefit assessment. (Int J Cardiovasc Sci. 2017;30(6)517-525)

Keywords: Atrial Fibrillation; Hemorrhage; Outpatient Clinics; Hospital.



Performance of Diagnostic Tests for Intermediate Probabilities of Coronary Heart Disease: A Decision Making Analysis
Performance dos Testes Diagnósticos na Probabilidade Intermediária de Doença Coronariana: Uma Análise para Auxílio à Tomada de Decisão

Clarissa Antunes Thiers, João Luis Barbosa, Bernardo Rangel Tura, Edilson Fernandes Arruda, Basilio de Bragança Pereira
International Journal of Cardiovascular Sciences. 2017;30(6)526-532

+   Abstract  
Patients with intermediate probability of coronary disease are a diagnostic challenge and it is precisely in this population where the degree of uncertainty is greater that the diagnostic tests have their greater applicability. However, according to the current definition, subjecting to tests a population with a disease probability between 10 and 90% can generate unnecessary tests and misleading results. Knowing the characteristics of each test, as well as risks and benefits of drug treatment for coronary disease and combining this information through diagnostic thresholds brings a new perspective to decision making. To review the origin of the currently recommended concepts of intermediate probability and to determine the thresholds for diagnosis and treatment of noninvasive tests and, based on them, propose a new concept of intermediate probability of coronary disease. Through the bibliographic review, meta‑analyses were extracted in which data of sensitivity, specificity, positive and negative likelihood ratio, risks and benefits of the tests and treatment were provided. Using an algorithm developed by Pauker et al. it was possible to obtain the diagnostic and treatment thresholds adjusted for each tests in question. The concept of intermediate probability of coronary disease is quite broad, ranging, according to the authors, between 10 and 90%, 1 and 92%, 15 and 85%, with different rationale. Considering the discriminatory power of each test, risks and treatment benefits, the diagnostic and treatment thresholds were defined for exercise testing (22-58%), eco-stress (10-72%), myocardial scintigraphy (12-80%), nuclear magnetic resonance (16-80%) and coronary angiotomography (6.7-81%). The decision to submit to diagnostic tests should be individualized, taking into account the diagnostic and treatment thresholds of each method in question.

Keywords: Coronary Artery Disease; Probability; Clinical Decision-Making; Diagnosis; Meta-Analysis.


The use of Cardiac 123I-mIBG Scintigraphy in Clinical Practice: The Necessity to Standardize!
Uso do 123I-mIBG Cardíaco na Rotina Clínica: A Necessidade de Padronizar!

Euclides Timóteo da Rocha, Wilson Eduardo Furlan Matos Alves, Derk O. Verschure e Hein J Verberne
International Journal of Cardiovascular Sciences. 2017;30(6)533-541

+   Abstract  
Cardiac adrenergic imaging has a great potential in a wide variety of clinical applications. Cardiac 123I-meta-iodobenzylguanidine (123I-mIBG) scintigraphy has a key role to assess chronic heart failure (CHF) by risk stratifying patients for cardiac events. The mIBG is a norepinephrine (NE) analogue that can evaluate cardiac sympathetic activity by assessing the down expression of β-adrenergic receptor (β-AR) in CHF. Furthermore, 123I-mIBG scintigraphy in combination with other parameters of left ventricular function can be used to identify the best responder for implantable cardiac devices, as well as to assess oncological cardiotoxicity. Despite its usefulness, 123I-mIBG scintigraphy is not widely performed because of the lack of standardization between different institutions. Thus, standardization and validation may contribute to its acceptance in clinical setting.

Keywords: Heart Failure; Myocardium/diagnostic imaging; Radionuclide Imaging; 3-Iodobenzylguanidine; Sympathetic Nervous System.



Dance, Heart Failure and Erectile Function: Perspective of Better Clinical Management?
Dança, Insuficiência Cardíaca e Função Erétil: Perspectiva de Melhor Manejo Clínico?

Tales de Carvalho, Ana Inês Gonzáles, Daiane Pereira Lima, Adair Roberto Soares dos Santos
International Journal of Cardiovascular Sciences. 2017;30(6)542-544

+   Abstract  
In the pathophysiology of heart failure (HF), attention has been directed to sympathetic hyperactivity and low‑intensity systemic inflammation, aspects also present in erectile dysfunction (ED). Physical exercise is a strategy that improves these parameters, which makes plausible the hypothesis that, when practiced through dance, exercise would provide better results. By combining physical activity and music, dance would be able to improve the functioning of central and peripheral neural networks additionally to other favorable mechanisms, contributing to the restoration of neurohormonal function and reduction of the inflammatory response, which would increase the efficacy of HF and ED treatment.

Keywords: Heart Failure / physiopathology; Exercise; Dance; Autonomic Nervous System; Inflammation.



Tachycardiomyopathy and Extracorporeal Membrane Oxygenation: A Case Report
Taquicardiomiopatia e Oxigenação Extracorpórea por Membrana: a Propósito de um Caso

Joana Malheiro, João Almeida, Daniel Caeiro, Adelaide Dias, Marlene Fonseca, Vasco Gama
International Journal of Cardiovascular Sciences. 2017;30(6)545-549

+   Introduction  
Tachycardiomyopathy (TCM) is a rare, but potentially reversible cause of cardiomyopathy and cardiogenic shock. It is defined by a global left ventricular systolic dysfunction secondary to persistent tachyarrhythmia, with partial (in patients with previous structural disease), or total recovery (in patients without previous structural disease) after cardiac rhythm normalization.1 The most commonly implicated arrhythmia is atrial fibrillation. The hemodynamic changes that characterize the patient with TCM include: increase in ventricular telediastolic and telesystolic volumes, global hypokinesis, increase in ventricular and pulmonary artery filling pressures, and, finally, decrease in ejection fraction (EF).1,2 It manifests clinically by congestive heart failure, and, in some cases, it may develop into cardiogenic shock. There are no specific methods to identify the presence of TCM. The diagnosis is usually attained retrospectively with normalization or improvement of left ventricular dysfunction, through tachyarrhythmia reversion or control. The most frequent complications of TCM are embolic events, complications due to the evolution of arrhythmia severity with degeneration to Ventricular Tachycardia (VT)/Ventricular Fibrillation (VF) and cardiogenic shock.3
The treatment includes measures of hemodynamic support, frequency control, and reversion to sinus rhythm, when possible.2 Extracorporeal Membrane Oxygenation (ECMO) is a mechanical device that ensures blood oxygenation and perfusion of the main organs for prolonged periods of time in patients with lung and/or heart failure.4 The use of this device allows the patient to remain alive and hemodynamically stable, working as a bridge to eventual recovery, transplantation, decision-making or even as a “bridge to another bridge” (for instance, as a bridge to left ventricular assist device – LVAD – as target therapeutics).
In cardiogenic shock of potentially reversible etiology, this measure can be lifesaving, as it temporarily assumes cardiac function during the refractory, intrinsic, and reversible phase of cardiogenic shock until patient recovery, minimizing the myocardial effort, improving organ perfusion, and preserving renal function.4 The authors describe a case of a patient with cardiogenic shock secondary to TCM where the use of ECMO was very important in her evolution.

Keywords: Cardiomyopathies; Tachycardia; Shock, Cardiogenic; Extracorporeal Membrane Oxygenation; Atrial Fibrillation.


Familial Hypercholesterolemia: the Importance of Early Diagnosis and Management
Hipercolesterolemia Familiar: a Importância do Diagnóstico e Tratamento Precoces

Ana Flavia Cassini Cunha e Iliana Ribeiro
International Journal of Cardiovascular Sciences. 2017;30(6)550-553

+   Introduction  
Familial Hypercholesterolemia (FH) is an autosomal dominant hereditary disease, a genetic disease of lipoprotein metabolism, mainly due to a defect in the LDLR gene encoding the LDL receptor.1-4 The diagnosis is established by clinical and laboratory criteria and should always be a diagnostic hypothesis in patients with low-density lipoprotein cholesterol (LDLc) levels greater than 190 mg/dL; and can be confirmed by genetic tests that determine the mutation.1,2 Some diagnostic criteria have been proposed in an attempt to standardize and formalize the diagnosis of FH, such as the Dutch Lipid Clinic Network (Dutch MEDPED).1 This calculates a patient score based on anamnesis data and physical and laboratory tests such as elevated rates of LDLc; characteristics such as tendinous xanthomas and corneal arch; family history of hypercholesterolemia and/or early coronary artery disease (man < 55 years and woman < 60 years) and identification of genetic mutations.1,3 The score determines the probability of an FH diagnosis as possible, probable or definitive FH.1 The most common mutation related to FH is in the gene encoding the LDL receptor, resulting in LDL receptors with functional reductions in their ability to remove LDLc from the circulation.3 There are two distinct phenotypes: the homozygous form, where two defective genes are inherited and LDL receptors have no functionality; a rare form, 1 in 1 million individuals and in this case are observed LDL levels > 650 mg/dL; and the heterozygous form, where a gene defective to the LDL receptor is inherited from one parent and a normal gene from the other.1 The absence of a functional gene causes an increase in the plasma level of LDLc; most frequently affects 1 in 500 individuals with LDL levels > 200 mg/dL.1 The homozygous form tends to present cardiovascular involvement already in childhood.1 The mutation may also be secondary to defects in the APOB gene encoding apolipoprotein B100, or by functional gain mutations in the pro-protein convertase subutilisin/kexin type 9 (PCSK) gene. -9).1,3,4 In patients with heterozygous FH the LDL particles circulate longer, being more subject to oxidation and chemical transformations that result in high uptake of LDL modified by macrophages, triggering pro-atherogenic mechanisms, causing atherosclerosis, coronary artery disease and arterial disease peripheral.1 The nutritional therapies, medication, and regular physical exercises help to control LDL levels and to prevent cardiovascular disease.1-3 It is recommended to reduce the intake of foods rich in cholesterol and saturated fatty acids.1-3 Pharmacological therapy is performed with high-potency statins, such as Atorvastatin (10-80 mg) and Rosuvastatin (10-40mg), in order to obtain a reduction of more than 50% of the baseline level.1 In patients with intolerant to statin therapy, other hypolipidemic agents, such as ezetimibe, niacin or cholestyramine may be used; and may be also combined with each others in patients who are poorly responding to single statin therapy.1,3 Drug therapy should be individually prescribed and maintained in the long term, with regular medical follow-up always evaluating liver (TGO/TGP) and muscular (CPK) enzymes.1,2 Lipid profile screening is recommended in all individuals over 10 years of age and in all first degree relatives of individuals diagnosed as having FH.1 In the presence of risk factors, clinical signs of FH or atherosclerotic disease, the lipid profile should be considered from 02 years old on.1
In this report, we describe the case of a patient in the fourth decade of life with Familial Hypercholesterolemia, who was successfully treated with high-potency statin.

Keywords: Doença Arterial Periférica, Aterosclerose, Indice Tornozelo-Braço, Hipercolesterolemia Tipo II.


Developed by Information Technology and Communication SBC | All rights reserved © Copyright 2016 | Sociedade Brasileira de Cardiologia | tecnologia@cardiol.br